1.09
+5.83%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Gain Therapeutics
From its filings with the US Securities and Exchange Commission
Gain Therapeutics is based in Bethesda, Maryland and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker GANX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2023, it reported revenue of $55,180.
We are a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (“CNS”) disorders, lysosomal storage disorders (“LSDs”), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology.
GT-02287 - our lead product candidate, for the treatment of Parkinson’s disease, is currently being evaluated in a Phase 1b study in people with Parkinson’s disease with or without a GBA1 mutation.
We have generated an extensive preclinical data package providing evidence of the mechanism of action and safety of GT-02287. In preclinical models of GBA1 and idiopathic Parkinson’s disease, GT-02287 has been shown to restore glucocerebrosidase, or GCase, function in the lysosome, improve mitochondrial health, reduce toxic lipid substrates and toxic forms of alpha-synuclein, reduce neuroinflammation, improve survival of dopaminergic neurons, increase dopamine levels, completely restore locomotor function and improve cognition, and reduce plasma-based neurodegeneration maker, neurofilament light chain (NfL) back to the level of healthy animals.
Quoted from its 10-K, filed 26 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 18 Mar 2021
- Employees
- 16
- Website
- gaintherapeutics.com ↗
- Head office
- 4800 HAMPDEN LANE, BETHESDA, MD, 20814
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Khalid IslamChairman of the Board, Founder, since 2017$84,506
- Mr. Gene MackPresident, Chief Executive Officer, Director, since 2024$737,720
- Mr. Gianluca FuggettaSenior Vice President - Finance, Principal Financial Officer$367,910
- Mr. Eric RichmanDirector, since 2020$54,506
- Dr. Dov GoldsteinIndependent Director$71,506
- Mr. Hans HaslerIndependent Director$68,006
- Ms. Gwen MelincoffIndependent Director$54,506
- Dr. Claude NicaiseIndependent Director$59,506
- Mr. Jeffrey RileyIndependent Director$70,006
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Gain Therapeutics Inc has a robust pipeline of innovative drug candidates targeting neurological disorders, including lysosomal storage disorders.
- The company has a strong team of experienced scientists and researchers who possess deep expertise in protein folding and drug design, allowing them to develop novel therapeutics.
- Gain Therapeutics Inc's unique proprietary platform technology, Site-Directed Enzyme Enhancement Therapy (SEE-Tx), enables the identification and optimization of small molecules that enhance enzymes' activity, presenting significant opportunities for therapeutic advancements.
Weaknesses
- As a relatively small biotech company, Gain Therapeutics Inc may face resource constraints, limiting their ability to conduct large-scale clinical trials or commercialize their drug candidates independently.
- The success of the company heavily relies on the effectiveness and safety of its drug candidates, leaving potential vulnerabilities in case of unforeseen adverse effects or regulatory setbacks.
Opportunities
- There is a growing global market for therapeutics targeting neurological disorders, providing ample opportunities for Gain Therapeutics Inc to address unmet medical needs and capture significant market share.
- The company can explore strategic partnerships or licensing agreements with larger pharmaceutical companies to leverage their expertise, financial resources, and distribution networks in order to accelerate drug development and maximize commercial success.
- Advancements in precision medicine and personalized therapies present an opportunity for Gain Therapeutics Inc to tailor their drug candidates to specific patient populations, potentially improving treatment outcomes and increasing market adoption.
Threats
- The highly competitive pharmaceutical industry poses a threat, as other established companies and biotech startups are also actively engaged in developing therapies for neurological disorders.
- Regulatory hurdles and stringent approval processes can delay the development and commercialization of drug candidates, exposing Gain Therapeutics Inc to time and cost risks.
- External factors, such as changes in healthcare policies or economic downturns, can impact market conditions and limit patient access to innovative therapies, potentially affecting the company's revenue and growth prospects.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.